Patents by Inventor Da Seul Im

Da Seul Im has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240270720
    Abstract: Disclosed herein are an indazole yl benzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, relieving or treating a protein kinase-related disease, including the derivative or the salt as an active ingredient, and the like. Further disclosed herein is a method for preventing or treating cancers, inflammatory diseases, or osteoporosis including administering the indazole yl benzimidazole derivative. The indazole yl benzimidazole derivative selectively inhibits Fms-like tyrosine kinase 3 (FLT3) when administered to a subject, and thus may be utilized for preventing, relieving or treating cancers including leukemia, inflammatory diseases including arthritis, or osteoporosis.
    Type: Application
    Filed: July 11, 2022
    Publication date: August 15, 2024
    Inventors: Jung Mi HAH, Da Seul IM
  • Publication number: 20230357164
    Abstract: The present invention relates to a novel quinazoline derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel quinazoline derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity against FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Inventors: Jung-Mi Hah, Da Seul Im
  • Publication number: 20220315573
    Abstract: The present invention relates to a novel benzimidazole derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity against FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).
    Type: Application
    Filed: August 12, 2020
    Publication date: October 6, 2022
    Applicant: Industry-University Cooperation Foundation Hangyang University Erica Campus
    Inventors: Jung Mi Hah, Da Seul Im